Taking people in Lettország4. fázis
A Rollover Study to Follow the Long-term Durability of Response to UGN-103 in Participants With Recurrent Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer (LG-IR-NMIBC) From Study BL013
Key facts
- Where
- Daugavpils, Liepaja és Riga, LettországSee the 4 sites
- Phase
- 4. fázis
Where in Lettország
- Daugavpils regionala slimnica SIADaugavpils, LettországTaking people
- Liepajas Regionala Slimnica SIALiepaja, LettországTaking people
- Pauls Stradins Clinical University HospitalRiga, LettországTaking people
- Rigas Austrumu kliniska universitates slimnica SIARiga, LettországTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Urogen Pharma Ltd.
- Trial code
- EU 2026-526359-75-00
- Record updated
- 2026. szeptember 15.
- Original description
Collect long-term durability of response data from participants with an ongoing complete response to UGN-103 at the end of Study BL013Read full original descriptionShow less
A Rollover Study to Follow the Long-term Durability of Response to UGN-103 in Participants From Study BL013
Collect long-term durability of response data from participants with an ongoing complete response to UGN-103 at the end of Study BL013
Inclusion: Participant has provided written informed consent for the rollover study; Participant completed Study BL013 with an ongoing CR.
Exclusion: Participant has not provided written informed consent for the rollover protocol; 2.Participant did not complete Study BL013 with an ongoing CR.